Systemic sclerosis & Raynaud's

Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures

Arthritis RheumatolPublished Secondary analysis of the SCOT randomised trial

Authors' conclusion

Paralleling the observed clinical benefit, HSCT leads to durable long-term normalization of the molecular signature in SSc, with completion of immune resetting to 54 months after HSCT.

Study context

Population
Systemic sclerosis (SSc) participants of the SCOT trial with peripheral blood cell (PBC) samples at baseline, 38 and 54 months after randomization; healthy controls30 with 38-month and 26 with 54-month samples
Comparison
Myeloablation followed by hematopoietic stem cell transplantation (HSCT) vs 12 months of IV CYC
Primary endpoint
Global PBC transcript (gene expression module) changes
Follow-up
38 and 54 months after randomization
Methodological detailslongitudinal gene expression study, paired comparison to baseline
  • Longitudinal gene expression study
  • Paired comparison to baseline

Primary result

As reported in the abstract

PBC gene expression modules vs baseline (paired) · 38 and 54 months
  • HSCT: significant down-regulation of interferon modules and up-regulation of cytotoxic/NK module at 38 and 54 months, indicating long-term normalization of baseline SSc signature
  • CYC: no differentially expressed modules
  • 38-month samples: HSCT = 19, CYC = 11; 54-month samples: HSCT = 16, CYC = 11

Further findings

PBC gene expression modules vs healthy controls · 38 and 54 months

HSCT at 38 months: up-regulation of B cell and plasmablast modules, down-regulation of myeloid and inflammation modules
HSCT at 54 months: no differentially expressed modules vs healthy controls, suggesting completion of immune reconstitution
CYC: continued SSc transcript signature vs controls at both time points

Original publication

Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures. Arthritis Rheumatol. Published 29 April 2024. doi:10.1002/art.42847

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.